Table 2.

Extracellular miRNA markers from blood or faecal specimen. AUC, area under the curve.

source	miRNA	case (n)	control (n)	sensitivity (%)	specificity (%)	AUC (95% CI)	detection method	clinical use	ref.
plasma	miR-21	31	34	65	85	—	qPCR	diagnosis	[67]
		186	53	82.8	90.6	0.919 (0.87–0.96)	qPCR	diagnosis and prognosis	[68]
	miR-6826	93	—	—	—	3.670	qPCR	prediction for a poor response to vaccine treatment	[69]
	miR-122	543	—	—	—	—	array microRNA cards	prognosis	[70]
serum	miR-24-2	228	68	—	—	—	qPCR	diagnosis	[71]
	miR-139-3p	117	90	96.6	97.8	0.9935	qPCR	diagnosis	[72]
	miR-139-5p	53	—	64	80	0.59–0.87	qPCR	prognosis	[73]
	miR-135a-5p	60	40	—	—	0.832 (0.73–0.93)	qPCR	diagnosis	[74]
		60	50			0.875 (0.80–0.95)
	miR-203	330	—	—	—	—	qPCR	prognosis and metastasis prediction	[75]
	(miR-21 + miR-29 + miR-92 +miR-125 +miR-223)	85	78	84.7	98.7	0.952	qPCR	diagnosis	[76]
	miR-24	111	130	78.38	83.85	0.839	qPCR	early detection	[77]
	miR-320a			92.79	73.08	0.886
	miR-423-5p			91.89	70.77	0.833
	(miR-24 + miR-320a +miR-423-5p)			92.79	70.77	0.899
plasma exosomes	miR-21	326	—	—	—	—	TaqMan miRNA assays	prediction of recurrence and poor prognosis in CRC patients with TNM stage II, III or IV.	[78]
	miR-6803-5p	168	—	—	—	—	qPCR	diagnosis and prognosis	[79]
	miR-17-5p	18	10	—	—	0.897 (0.80–0.99)	qPCR	prognosis	[80]
		11	10	—	—	0.841 (0.72–0.96)
	miR-92a-3p	18	10	—	—	0.845 (0.72–0.97)
		11	10	—	—	0.854 (0.74–0.97)
saliva	miR-21	34	34	97	91	—	qPCR	diagnosis	[67]
faecal	miR-4478	40	16	—	—	—	SYBR Green miScript PCR system	diagnosis	[81]
	miR-1295b-3p	40	16	—	—	—